Ocular Manifestations in Homocystinuria
Posted May 31, 2018
History of Present Illness
An 18-year-old male presented to clinic for regular monitoring of ocular manifestations of methionine synthase deficiency type homocystinuria, specifically cobalamin deficiency of the Cb1G subtype. He complained of some photophobia and intermittent inward turning of his eyes. Additionally, he was noted to have nystagmus and subnormal vision.
The patient was first evaluated by ophthalmology at four months of age at which time he was noted to have large amplitude horizontal pendular nystagmus and poor fixation. His dilated fundus exam (DFE) showed indistinct foveal reflexes and retinal pigment epithelium (RPE) granularity. Several months later, the patient was re-examined and noted to have high astigmatism in both eyes (OU) for which he was given glasses. At about one year of age an electroretinogram (ERG) was performed, which showed generalized reduction. Over time, he developed an esotropia of 40-50 prism diopters and mild amblyopia in the left eye (OS). He ultimately underwent bilateral medial rectus recessions of 5.5 mm at six years of age.
At age 11 years, his best corrected vision was noted to be 20/50 in the right eye (OD) and 20/60 OS. He had progressive myopia and astigmatism, especially OS. However, no ectopia lentis was detected. Fundus examination demonstrated yellowish flecks in the maculae OU, which were suspicious for Stargardt disease. A workup for hereditary retinal degeneration was performed and was remarkable for just one mutation in ABCA, which was not diagnostic for autosomal recessive Stargardt disease. An ERG was repeated at age 16 due to subnormal vision which showed abnormal cone function. Optical coherence tomography (OCT) at the time showed loss of foveal depression and parafoveal outer retinal atrophy.
Additionally, the patient has multiple systemic manifestations of homocystinuria, including developmental delay, megaloblastic anemia, seizures, and chronic kidney disease. Despite early intervention in a metabolic program, including dietary restriction and prescription of betaine, his homocysteine levels were never well-controlled.
Past Ocular History
- Horizontal pendular nystagmus
- Esotropia status post bilateral medial rectus recessions of 5.5 mm
- Mild amblyopia OS, treated with atropine drops in the right eye (OD)
Past Medical History
- Homocystinuria due to Methionine Synthase Deficiency (cobalamin deficiency, Cb1G subtype) with the following associated systemic manifestations:
- Developmental delay
- Megaloblastic anemia
- Chronic kidney disease (hemolytic uremic syndrome as a neonate)
- Pituitary dysfunction
- Growth hormone deficiency
- Obesity (Body Mass Index 30.05)
- Ascorbic Acid (Vitamin C) 1000 mg by mouth, daily
- Aspirin, 81 mg by mouth, daily
- Betaine, 20 g a day by mouth divided into 6 doses, daily
- Calcium Carbonate (Vitamin D3), 1000 mg, daily
- Hydroxyocobalamin Powder, 0.3 mg/kg/day (Intramuscular)
- Levothyroxine, 125 mcg by mouth, daily
- Lisinopril, 20 mg by mouth, daily
- L-methyl-B6-B-12, 3-35-2 mg tablets; one tablet by mouth, twice daily
- Melatonin, 500 mcg by mouth, every night
- Methionine/Lysine/Cyst/Supox/Cat (Methionine-200 PO), 200 mg by mouth, daily
- Multivitamin with iron by mouth, daily
- Psyllium, 2.6 g by mouth, daily
- Sennosides 8.6 mg tablet, 1 tablet by mouth, twice daily
- No family history of retinal disease
Review of Systems
- Negative except as documented in the history of present illness
Visual Acuity (VA) with correction
- OD: 20/40
- OS: 20/60
- OD: -4.00 +3.25 x 100, VA: 20/40
- OS: -4.50 + 4.25 x 087, VA: 20/60
Other Visual Acuity Tests
Color Vision (Ishihara):
- OD: 2.5/14 color plates
- OS: 1.5/14 color plates
- Full extraocular motility
- Manifest horizontal nystagmus with latent component in side gazes
- Abnormal head posture: left face turn of 20 degrees
- Alternate cover test with OS as fixing eye
- Primary gaze at near: intermittent esotropia of 5 prism diopters
- Primary gaze at distance: flick of esotropia
Intraocular Pressure (IOP)
- OD: 11 mmHg
- OS: 13 mmHg
- Equal and reactive to light, no relative afferent pupillary defect in either eye
- OD: Normal
- OS: Normal
Slit lamp exam
- Lids/lashes: Normal OU
- Conjunctiva/sclera: Clear and quiet OU
- Cornea: Clear OU
- Anterior chamber: Deep and quiet OU
- Iris: Normal architecture, no iridodonesis in either eye
- Lens: Normal without phacodonesis
Dilated fundus examination (DFE)
- Vitreous: Normal OU?
- Disc: Normal OU
- Cup-to-disc ratio: 0.1 OU
- Macula: Whitish dots OU
- Vessels: Normal OU
- Periphery: Yellow linear flecks throughout the periphery OU
Homocysteine: 165.4 µmol/L (normal <= 10.0 µmol/L)
At this point in the patient's clinical course, there was concern for retinal changes due to homocystinuria, in the setting of significantly elevated blood homocysteine levels with increasing numbers of whitish intraretinal spots, both within the maculae and in the periphery. He was taking the recommended treatment of hydroxycobalalmin injections and betaine supplements, but his homocysteine level was still difficult to control. He had tried the recommended diet for his condition but had difficulty adhering to it. He was encouraged to work with a nutritionist and his other physicians in order to better control his homocysteine levels. He will return to the ophthalmology clinic for close follow up with repeat examination and imaging.
- Homocystinuria with associated retinal degeneration
Homocystinuria, or accumulation of homocysteine in the blood and urine, is due to an inborn error in methionine metabolism that is commonly inherited in an autosomal recessive fashion. The prevalence of all types of homocystinuria is estimated to be 1: 344,000 . There are different types of homocystinuria with the most common type caused by a deficiency in the enzyme cystathionine beta-synthase, which occurs in about 1:50,000 births [2 ,3]. This type of homocystinuria is usually detected on newborn screening tests.
To better describe the pathophysiology of homocystinuria, it is separated into three major categories based on the site of the metabolic defect. Type 1 is due to a deficiency in cystathionine beta-synthase, which converts homocysteine to cystathionine. Type 2 is due to defective methylcobalamin synthesis, which helps to convert homocysteine to methionine. Type 3 is due to an abnormality in methylene tetrahydrofolate reductase, which also helps to convert homocysteine to methionine . These types have also been organized into broader categories: homocystinuria due to a defect in the transsulfuration pathway of homocysteine (type 1) and homocystinuria due to a defect the methylation pathway of homocysteine (types 2 and 3) . Figures 5 and 6 show these different pathways and the sites of the enzymatic defects [4 ,5].
In this discussion, we will focus on homocystinuria due to methionine synthase deficiency, which is a defect in the methylation pathway of homocysteine. This specific deficiency is characterized by homocystinuria, hyperhomocysteinemia, and hypomethioninemia, without methylmalonic aciduria . Methionine synthase catalyzes the methylation of homocysteine to methionine and can be caused by deficiency in methylene tetrahydrofolate reductase or by deficiency of methylcobalamin cofactors . The patient in this case possesses the cb1G defect, or cobalamin G deficiency, leading to a deficiency in methylcobalamin cofactors . Figure 6 demonstrates the location of the Cb1G defect [4 ,5].
There have been few studies that offer theories for the pathophysiologic mechanisms underlying the ocular sequelae of homocystinuria. Poloschek et al. investigated ERG findings in those with methionine synthase deficiency and proposed that increased homocysteine levels decrease the transport of folates to photoreceptors, which in turn decrease intracellular anabolic processes, impacting cone photoreceptor function . They also commented that hyperhomocysteinemia may lead to microvascular damage in the retina, leading to reduced oscillatory potentials. It may also have toxic effects on the neurons of the ganglion cell layer, leading to deformed flash visual evoked potential (VEP) responses . Bacci et al. investigated OCT changes in patients with cobalamin C deficiency (cb1C) and commented that there may be reduced reuptake of methionine into the cone cell membrane during phototransduction, leading to a progressive maculopathy .
Ectopia lentis is prevalent in patients with homocystinuria. This is thought to be due to broken and matted zonular fibers that tend to break centrally and curl up against the lens . The lens often subluxates inferiorly and anteriorly and can cause pupillary block [2 ,3]. In cystathionine beta-synthase deficiency, ectopia lentis presents in most patients by age 5 years old if the homocystinuria is left untreated [2 ,3].
Many patients with homocystinuria also develop nystagmus early on in life. [6-9]. In patients with cobalamin C deficiency (cb1C), nystagmus is present in 64% .
In patients with homocystinuria due to an error in cobalamin processing, specifically cobalamin C type deficiency (cb1C), there have been many reports describing the presence of a progressive maculopathy [8 ,9]. Of note, cobalamin C type deficiency is different than cobalamin G type deficiency due to the presence of methylmalonic aciduria. One study of patients with cb1C disease showed that macular changes were present in 72% of patients that underwent ocular examination . There are various descriptions of the appearance of this maculopathy including pigment epithelial mottling, atrophic lesions, bull's eye appearance, and peripheral salt-and-pepper pigment changes [8 ,9].
Other ocular signs include progressive myopia, strabismus, iridodonesis, cataract, iris atrophy, retinal detachment, central retinal artery occlusion, optic atrophy, anterior staphylomas, sluggish pupillary response, and eyelid clonus [2 ,7 ,9 ,10].
There are many systemic signs and symptoms that are manifest with homocystinuria, such as developmental delay, failure to thrive, dental abnormalities, arachnodactyly, thromboembolic events, seizures, megaloblastic anemia, hypotonia, and feeding problems [3 ,4 ,6 ,9]. Thrombotic complications are obviously of high concern but have been more commonly reported in those patients with cystathionine beta-synthase deficiency rather than the other variants of homocystinuria .
OCT changes in patients with cb1C disease and maculopathy show loss of the external limiting membrane, myoid, ellipsoid, and interdigitation zones with preservation of the RPE in the foveal area . In some patients, there are hyperreflective material in the parafoveal area just anterior to the RPE . In patients with progressive maculopathy in cb1C disease, there is thinning and loss of the ganglion cell layer, outer nuclear layer, and photoreceptor layer on OCT [10 ,11].
ERGs have been performed in patients with homocystinuria, and evidence shows that these patients may show amplitudes that are reduced early in the course of the disease; often with the cones more affected than the rods . In patients with methionine synthase deficiency, single flash cone b wave, flicker, and oscillatory potential responses were reduced below the fifth percentile of age-matched normals . ERG under anesthesia on patients with cb1C disease shows 50% reduction in the scotopic b-wave and delay of the photopic a-wave and scotopic b-wave consistent with diffuse photoreceptor and bipolar cell dysfunction .
Homocystinuria is treated with vitamin supplementation and dietary restrictions. For patients with the cb1G defect, like the patient in this case, parenteral cobalamin supplementation is indicated as well as betaine supplementation, which acts as a methyl donor in the conversion of homocysteine to methionine (see Figure 5) [4 ,5]. Dietary restriction of protein is also indicated for some types of homocystinuria because it reduces methionine consumption which should in turn decrease homocysteine production [4 ,5]. Because methionine synthase deficiency may prevent the production of tetrahydrofolate, which can lead to folate deficiency and megaloblastic anemia, folate supplements can also be beneficial . A study specifically looking at patients with maculopathy due to homocystinuria caused by cb1C disease noted that clinical progression of retinopathy is not prevented by early systemic therapy to reduce toxic metabolites .
- Best Vitelliform Macular Dystrophy
- Stargardt Disease
- Pattern Dystrophy
- Familial Dominant Drusen
- Sorsby Macular Dystrophy
- North Carolina Macular Dystrophy
- Chloroquine and hydroxychloroquine maculopathy
- Drug induced crystalline maculopathies (tamoxifen)
- Macular Degeneration
- Ectopia Lentis et pupillae
- Exfoliation Syndrome
- Marfan Syndrome
- Ehlers-Danlos Syndrome
- Weill-Marchesani Syndrome
- Sulfite oxidase deficiency
EPIDEMIOLOGY OR ETIOLOGY
- Mazaheri A, Mostofizadeh N, Hashemipour M. Homocystinuria with Stroke and Positive Familial History. Adv Biomed Res 2017;6:132. https://PubMed.gov/29279830. DOI: 10.4103/2277-9175.217215
- Self JaL, Christopher The Lens. Taylor and Hoyt's Pediatric Ophthalmology and Strabismus Fifth Edition ed: Elsevier 2017; chapter 36; p. 337-345.
- Stamper RLM, Lieberman, Marc F MD, Drake, Michael V MD. Developmental and Childhood Glaucomas Becker-Shaffer's Diagnosis and Therapy of the Glaucomas Eighth Edition ed: Elsevier 2009; chapter 19; p. 294-329.
- Harding CO, Arnold G, Barness LA, Wolff JA, Rosenblatt DS. Functional methionine synthase deficiency due to cblG disorder: a report of two patients and a review. Am J Med Genet 1997;71(4):384-390. https://PubMed.gov/9286442
- Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA); 1993.
- Carmel R, Watkins, David, Rosenblatt, David. Megaloblastic Anemia Nathan and Oski's Hematology and Oncology of Infancy and Childhood. Eighth Edition ed: Saunders; 2015; chapter 10; p. 308-343.
- Poloschek CM, Fowler B, Unsold R, Lorenz B. Disturbed visual system function in methionine synthase deficiency. Graefes Arch Clin Exp Ophthalmol 2005;243(5):497-500. https://PubMed.gov/15931548. DOI: 10.1007/s00417-004-1044-2
- Bacci GM, Donati MA, Pasquini E, Munier F, Cavicchi C, Morrone A, Sodi A, Murro V, Garcia Segarra N, Defilippi C, Bussolin L, Caputo R. Optical coherence tomography morphology and evolution in cblC disease-related maculopathy in a case series of very young patients. Acta Ophthalmol 2017;95(8):e776-e782. https://PubMed.gov/28481040. DOI: 10.1111/aos.13441
- Agarwal AM. Hederodystrophic Disorders Affecting the Pigment Epithelium and Retina Gass' Atlas of Macular Diseases Fifth Edition ed: Saunders; 2011; chapter 5; p. 239-246.
- Brooks BP, Thompson AH, Sloan JL, Manoli I, Carrillo-Carrasco N, Zein WM, Venditti CP. Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency. Ophthalmology 2016;123(3):571-582. https://PubMed.gov/26825575. DOI: 10.1016/j.ophtha.2015.10.041
- Bonafede L, Ficicioglu CH, Serrano L, Han G, Morgan JI, Mills MD, Forbes BJ, Davidson SL, Binenbaum G, Kaplan PB, Nichols CW, Verloo P, Leroy BP, Maguire AM, Aleman TS. Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss. Invest Ophthalmol Vis Sci 2015;56(13):7875-7887. https://PubMed.gov/26658511. DOI: 10.1167/iovs.15-17857
Suggested Citation Format
Stiff HA, Drack AV. Homocystinuria. EyeRounds.org. posted May 30, 2018; Available from https://EyeRounds.org/cases/269-Homocystinuria.htm